1 / 9

STAR*D Objectives

Compare relative efficacy of different treatment options Goal is REMISSION, not just “response” Less than half of patients with depression remit with a single antidepressant Randomized comparisons of treatment options will define the next best step following previous treatment failure(s)

kagami
Download Presentation

STAR*D Objectives

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Compare relative efficacy of different treatment options Goal is REMISSION, not just “response” Less than half of patients with depression remit with a single antidepressant Randomized comparisons of treatment options will define the next best step following previous treatment failure(s) Identify predictors of remission to treatments Utilize simple self-reports as tools to improve patient collaboration and objectively evaluate treatment response STAR*D Objectives Rush AJ, et al. Control Clin Trials. 2004;25:119-142.

  2. N = 4000 outpatients aged 18 to 75 years old Primary diagnosis of nonpsychotic major depressive disorder, confirmed by study clinician Most Axis I comorbidities, other general medical conditions allowed Treatment setting: specialty and primary care HRSD17 score ≥14 at study entry 12–14 weeks per treatment level; 1-year naturalistic follow-up Equipoise-stratified, randomized design allowed patients to select treatment strategy and allowed randomization to different treatment options within the selected strategy STAR*D Study Overview Rush AJ, et al. Control Clin Trials. 2004;25:119-142.

  3. Baseline Demographics Trivedi MH, et al. Am J Psychiatry. 2006;163:28-40. Courtesy of A. John Rush, MD.

  4. Baseline Characteristics MDEs = major depressive episodes. Trivedi MH, et al. Am J Psychiatry. 2006;163:28-40. Courtesy of A. John Rush, MD.

  5. STAR*D Participant Flow into Level 1 Screened (N = 4790) Ineligible (163) or did not consent (613) (n = 749) Enrolled in Level 1 (n = 4041) HAM-D score <14a (n = 607) or HAM-D missing (n = 324) HAM-D score >14 (n = 3110) Failed to return (n = 234) Eligible for analysis (n = 2876) Exit (n = 592) Follow-up (n = 1083) Level 2 (n = 1201) a HAM-D = 17-item Hamilton Depression Rating Scale. Adapted from Trivedi MH, et al. Am J Psychiatry. 2006;163:28-40.

  6. Nonremitters treated w/ CIT Level 1: CIT + BUP-SR N = 354 VEN-XR N = 287 COG N = 204 SER N = 287 BUP-SR N = 287 CIT + COG N = 224 CIT + BUS N = 354 Randomized to BUP-SR or VEN-XR Level 2A: STAR*D Defining Evidence for Protocols—Level II Level 2: AUGMENT OPTIONS Randomized SWITCH OPTIONS Randomized If no satisfactory response to COG, then L2A BUP-SR, bupropion sustained-release; BUS, buspirone; CIT, citalopram; COG, cognitive therapy; SER: sertraline; VEN-XR, venlafaxine extended-release STAR-D III Research Design Methods.pdf. Available at: http://edc.gsph.pitt.edu/stard/public/Protocol/. Accessed June 25, 2008.

  7. Clinical presentation of patients with major depressive disorder (MDD) in primary and specialty care is similar General medical conditions minimally affect MDD symptoms Substance abuse minimally affects MDD symptoms Psychiatric comorbidities complicate remission MDD + substance abuse is more likely in younger males, but not more likely by ethnicity Patients with early-onset MDD have more severe, disabling, chronic, or recurrent conditions Patients with early-onset MDD have more comorbidities, poorer educational achievement, and lower likelihood of marriage Observations 1.Warden D, et al. Curr Psychiatry Rep. 2007;9:449-459. 2. Rush AJ, et al. Am J Psychiatry. 2006;163:1905-1917. 3. Trivedi MH, et al. Neuropsychopharmacology. 2007;32:2479-2489. 4. NIMH/Results for STAR*D Study. http://www.nimh.nih.gov/health/trials/practical/stard/index.shtml. Accessed April 2, 2008. 5. Rush AJ, et al. Psychiatric Annals. 2008;38:188-193.

  8. STAR*D provides new evidence to choose among treatment decisions for patients with major depressive disorder Maximum tolerated dose and lengthier dosing time may be needed to achieve remission 8–14 weeks adherence to treatment, including 4 weeks at maximum tolerated dose, was required If QIDS score is not reduced by 25% by week 9, participants recommended to move to the next level About half of the participants became symptom-free after the first 2 treatment levels Measurement-based tools improve adherence to therapy through patient education and collaboration Measure symptoms/side effects at each visit Clinical Implications 1. Warden D, et al. Curr Psychiatry Rep. 2007;9:449-459. 2. Rush AJ, et al. Am J Psychiatry. 2006;163:1905-1917. 3. Trivedi MH, et al. Neuropsychopharmacology. 2007;32:2479-2489. 4. NIMH/Results for STAR*D Study. http://www.nimh.nih.gov/health/trials/practical/stard/index.shtml. Accessed April 2, 2008. 5. Rush AJ, et al. Psychiatric Annals. 2008;38:188-193.

  9. Suggested Reading • World Health Organization. Depression. Available at: http://www.who.int/mental_health/management/depression/definition/en/. Accessed April 9, 2008. • Greenberg PA, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465-1475. • Trivedi MH, Rush AJ, Gaynes BN, et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care. Neuropsychopharmacology. 2007;32:2479-2489. • National Institute of Mental Health. Results for Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study. Available at: http://www.nimh.nih.gov/health/trials/practical/stard/index.shtml. Accessed April 2, 2008. • Warden D, Rush AH, Trivedi MH, Fava M, Wisniewski SR. The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9:449-459. • Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905-1917.

More Related